PANDEMIC REPORT: COVID-19 drugs already in use | More on antibodies | Fighting CRS

COVID-19 drugs already in use

ANN ARBOR, MI—Could the next therapy for COVID-19 already be at your local pharmacy? A study from the University of Michigan reveals several drug contenders already in use for other purposes—including one dietary supplement—have been shown to block or reduce SARS-CoV-2 infection in cells.

Antibody against COVID variants

ST. LOUIS, MO—At the Washington University School of Medicine, Dr. Laura VanBlargan, Ph.D., co-led a study that identified an antibody that is highly protective against a broad range of COVID variants.

Drug candidate for fighting CRS

PITTSBURGH, PA—Biotech company CytoAgents has a lead drug candidate for treating life-threatening symptoms associated with Cytokine Release Syndrome (CRS). CRS is an over-reaction by the immune system that causes systematic inflammation, a common reaction to COVID-19.

Treatment for children’s inflammatory syndrome

RALEIGH, NC—Multisystem inflammatory syndrome in children (MIS-C) is a rare and serious complication of COVID-19. 9 Meters BioPharma, Inc. will collaborate with the European Biomedical Research Institute of Salerno, Italy to study larazotide for treatment of MIS-C.